Skip to main content
Premium Trial:

Request an Annual Quote

Alexion, Sema4 Partner to Improve Diagnosis of Rare Diseases

CHICAGO (GenomeWeb) – Alexion Pharmaceuticals is teaming with sequencing and informatics startup Sema4 in an effort to improve diagnosis of rare diseases and speed drug discovery.

Sema4, a spinout from Mount Sinai Health System in New York, will bring its knowledge in next-generation sequencing and genome interpretation to Alexion's SmartPanel precision medicine platform, the two companies announced this morning.

"This collaboration will help accelerate an accurate diagnosis for patients with rare genetic diseases and reduce the multiyear process that many families face before receiving a diagnosis," John Reynders, Alexion's vice president of data sciences, genomics, and bioinformatics, said in a statement.

Notably, Alexion and Sema4 will be searching for evidence of "genomic shields" that might help patients with known disease-causing mutations resist development of the relevant conditions.

"The advanced data science and bioinformatics capabilities that Alexion and Sema4 both bring to the table will enable us to decode these unique patients who are resistant to their genetic propensity for disease," Sema4 CEO Eric Schadt explained. "By building systems biology models of the rare disease biology in these patients, we can identify novel points of therapeutic intervention for patients."

Financial and other terms of the deal were not disclosed.

In May, Alexion partnered with Rady Children's Institute for Genomic Medicine in San Diego to develop SmartPanel for use in newborns with rare genetic disorders.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.